3 news items
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
ZYME
17 Jun 24
&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment," said Paul Moore, Chief Scientific Officer
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
ZYME
10 Jun 24
-GEA-01)." "We further our mission by collaborating with other innovative companies to advance the development and delivery of impactful
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
SNDX
ZYME
28 Mar 24
with difficult-to-treat cancers and other serious diseases is evident in their innovative approach in developing next-generation product candidates. I am
- Prev
- 1
- Next